InsidersTradesSigma
Track the ATAI Life Sciences N.V. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, ATAI Life Sciences N.V. has recorded 44 reports. Market capitalisation: €2.6bn. The latest transaction was reported on 2 October 2025 (C). Among the most active insiders: Apeiron Investment Group Ltd.. All data is free.
44
Insider Decl.
n/a
Thresholds
€62m
24 ops.
Buy Volume
€708,418
9 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ATAI Life Sciences N.V. Buy (bullish), based on 8 analysts. Average price target: US$11.78.
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 October 2025
Declarations44 total
2,367,200 sharesCommon SharesSEC:0001193125-25-228361:0
8,675,799 shares@ US$2.1931.2% of flowCommon SharesSEC:0000950170-25-109858:0
Canonical exit: 12 Nov 2025 (T+90)
1,800,000 shares@ US$1.405.2% of flowCommon SharesSEC:0000950170-25-043942:0
Canonical exit: 22 Jun 2025 (T+90)
13,161 shares@ US$1.35100.0% of flowCommon SharesSEC:0001140361-25-010112:0
33,545 shares@ US$1.3547.0% of flowCommon SharesSEC:0001140361-25-010113:0
48,563 shares@ US$1.3549.5% of flowCommon SharesSEC:0001140361-25-010116:0
75,418 shares@ US$1.3532.6% of flowCommon SharesSEC:0001140361-25-010114:0
11,563 shares@ US$1.35100.0% of flowCommon SharesSEC:0001140361-25-010115:0
100,000 sharesCommon SharesSEC:0001140361-25-009511:0
100,000 sharesCommon SharesSEC:0001140361-25-009510:0
20,000 sharesCommon SharesSEC:0001140361-25-009514:0
32,500 sharesCommon SharesSEC:0001140361-25-009513:0
175,000 sharesCommon SharesSEC:0001140361-25-009512:0
10,835,718 shares@ US$2.1048.5% of flowCommon SharesSEC:0000950170-25-023436:0
Canonical exit: 15 May 2025 (T+90)
151,303 shares@ US$1.9253.8% of flowCommon SharesSEC:0001140361-24-026915:0
35,801 shares@ US$1.8550.5% of flowCommon SharesSEC:0001140361-24-018027:0
27,410 shares@ US$1.8553.0% of flowCommon SharesSEC:0001140361-24-018029:0
61,640 shares@ US$1.8536.8% of flowCommon SharesSEC:0001140361-24-018028:0
100,000 sharesCommon SharesSEC:0001140361-24-013628:0
350,000 sharesCommon SharesSEC:0001140361-24-013625:0
100,000 sharesCommon SharesSEC:0001140361-24-013627:0
175,000 sharesCommon SharesSEC:0001140361-24-013626:0
20,000 shares@ US$1.1564.3% of flowCommon SharesSEC:0001140361-23-053957:0
Canonical exit: 14 Feb 2024 (T+90)
40,000 shares@ US$1.449210.9% of flowCommon SharesSEC:0000950170-23-048195:0
Canonical exit: 12 Dec 2023 (T+90)
70,000 shares@ US$1.479419.2% of flowCommon SharesSEC:0000899243-23-010034:0
Canonical exit: 27 Jun 2023 (T+90)
25 of 44 declarations
About ATAI Life Sciences N.V.
ATAI Life Sciences N.V. (ticker: ATAI) is a United States-listed biopharmaceutical company trading on the NASDAQ, focused on developing innovative treatments for mental health disorders. Founded in 2018, the company was created in response to the persistent unmet need in psychiatry, where many patients with depression, anxiety, addiction, and other difficult-to-treat conditions still do not benefit adequately from existing therapies. ATAI operates as a platform-style “company builder,” combining capital allocation, scientific expertise, regulatory know-how, and operational support to incubate and advance differentiated therapeutic programs, including psychedelic-based and other novel compounds with potential clinical value. The company’s roots are in Berlin, and it maintains an international footprint with offices and operations linked to New York, reflecting a transatlantic structure aimed at addressing a global mental-health market. Its pipeline is centered on clinical-stage assets such as VLS-01, a buccal-film formulation of DMT being developed for treatment-resistant depression; BPL-003, an intranasal mebufotenin benzoate program for treatment-resistant depression advanced through a strategic investment with Beckley Psytech; and EMP-01, an oral R-MDMA program targeting social anxiety disorder. This diversified pipeline is important from an investment perspective because it reduces single-asset dependency while keeping the company exposed to the broader re-rating potential of next-generation psychiatric therapies. In competitive terms, ATAI participates in a highly demanding field where success depends on clinical execution, tolerability, regulatory progress, intellectual-property strength, and access to capital. The recent news flow has included continued advancement of VLS-01 into Phase 1b, ongoing development work around BPL-003, and 2025 financial updates that reinforce ATAI’s status as a clinical-stage company without product commercialization yet. For European investors, ATAI is best viewed as a high-risk, high-upside biotech exposure tied to a very large and structurally under-served addressable market. Its strategic focus on mental health remains compelling, but the investment case still hinges on clinical data readouts, regulatory milestones, and financing discipline.
